# 1-Year Follow up to the 1473-IMIQ Study

> **NCT00114023** · — · COMPLETED · sponsor: **Graceway Pharmaceuticals, LLC** · enrollment: 84 (—)

## Conditions studied

- Keratosis

## Interventions

- **DRUG:** Imiquimod 5% cream

## Key facts

- **NCT ID:** NCT00114023
- **Lead sponsor:** Graceway Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 84 (—)
- **Last updated:** 2007-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00114023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00114023, "1-Year Follow up to the 1473-IMIQ Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00114023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*